298 JOURNAL OF THE SOCIETY OF COSMETIC CHEMISTS The same resin buffer systems that are used for the treatment of poison ivy skin infections can also be utilized for the prevention of such skin ailments. When an ion exchange resin system is applied to the skin in the form of a protective cream, it will sequester and inactivate botanical irritants and also other irritants responsible for certain types of industrial dermatitis. FORMULATION CONSIDERATIONS When lotions or ointments are desired, the ion exchange resin component or components should be incorporated into a liquid base that is either hydrophilic or miscible with water. Ointments may be made with a hydrophilic base, a gelatinous aqueous paste, or other ointment bases containing inert organic ingredients such as thickened mineral oils, pet- rolatum or other conventional bases. Hydrophobic bases should be avoided because they coat the ion exchange resin component, reducing its ion exchange activity. An ion exchange dusting powder may be prepared by mixing the ion exchange resin component in a powder base of such materials as talc, starch, kaolin, zinc oxide or titanium oxide. Zinc or magnesium stearate or laurate or other long chain carboxylates may be used for dispersion and adhesion. However, ion exchange resins themselves have excellent substantivity on the skin because of the co-action of their functional groups with functional groups of an opposite charge of the skin. If desired, pigments may be used as tinting materials and perfumes may be added. Drugs may be admixed with the ion exchange resin dusting powder or with the powder base or may be complexed ionically with the ion exchange resin component. The ion exchange resin may be used to release ther- apeutic amounts of ionic materials such as local anesthetics or antibiotics. Such materials are available for action at the site where the powder is applied, and the exchange supplies the desired action of regulating the pH of the surface area. (Received March 5, 1962) REFERENCES (1) Martin, Gustav J., and Wilkinson, John, Gastroenterology, 6, No. 4, 1 (1946). (2) Martz, N. L., Kohlstaedt, K. G., and Helmer, O. M., Proc. Central Soc. Clin. Res., 23rd Atnnual Meeting, Chicago, 23, 70, Abst. 90 (1950). (3) Segal, Harry L., Miller, Leon L., Morton, John J., and Young, Henry Y., Gastroenterology, 16, No. 2, 380 (1950). (4) Quintos, Florencio N., 5% Philippine Med. Atssoc., 26, 155 (1950). (5) Cass, Leo J., and Frederik, Wilhel, S., New Engl. 5% Med., 259, 1108 (1958). (6) Becker, Bernard A., and Swift, John G., Toxicol. Atppl. Pharmacol., 1, 42 (1959). (7) Chow, Bacon, "Mechanism of Absorption of Vitamin Bp2," in "World Review of Nutrition and Dietetics," Philadelphia, J. B. Lippincott Co. (1959), p. 135-138. (8) VanAbbe, N.J., and Rees, J. T., 5 t. Arm. Pharm./lssoc., $ci. Ed., 47, 487 (1958). (9) Winters, James C., J. Soc. CoswETm Ct4v. mSTS, 7, 256 (1956).

RESINS AND THEIR APPLICATION TO DRUG AND.•COSMETIC PRODUCTS 299 (10) Eugere, E. J., Lynch, V. D., and Thoms, R. K., Univ. Conn., School of Pharmacy, "The Antitrichomonal Activity of Ion Exchange Resins," private communication. (11) Eugere, E. J., Lynch, V. D., and Thoms, R. K., Univ. Conn. School of Pharmacy, "The Inhibitory Effect of an Ion Exchange Resin," private communication. (12) Richardson, G. S., and Purdy, R. H., Surg. Forum, 11,329 (1960). (13) Thurmon, F. M., U.S. Patent 2,838,440 (1958). (14) Thurmon, F. M., U.S. Patent 2,919,230 (1959). (15) Thurmon, F. M., U.S. Patent 2,883,324 (1959) (16) Thurmon, F. M., U.S. Patent 2,764,518 (1956). (17) Thurmon, F. M., U.S. Patent 2,857,311 (1958). (18) Thurmon, F. M., U.S. Patent 2,684,321 (1954). (19) Thurmon, F. M., U.S. Patent 2,653,902 (1953).